Evidence map›Paper›PMID 40621293›Full record

ArticleCureus2025

Carfilzomib-Induced Thrombotic Microangiopathy: A Case Report on a Rare Complication.

Manogna Pendyala, Ayesha Tahir, Purnoor Kaur, Abhay Shelke, Vinod Khatri

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manogna PendyalaDepartment of Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.
Ayesha TahirDepartment of Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.
Purnoor KaurDepartment of Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.
Abhay ShelkeDepartment of Hematology Oncology, Bon Secours Mercy Health, Toledo, USA.
Vinod KhatriDepartment of Pulmonary and Critical Care Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury due to microvascular thrombosis. Drug-induced TMA is a recognized subtype, but its diagnosis is challenging due to the absence of specific laboratory tests to identify the agent. Many chemotherapeutic agents are associated with TMA. Carfilzomib is a newer chemotherapeutic agent and is an uncommon cause of TMA. We report the case of a 71-year-old female patient undergoing treatment with carfilzomib for refractory multiple myeloma who developed suspected carfilzomib-induced TMA and was managed successfully with plasmapheresis and hemodialysis leading to clinical improvement.

Indexed as

acute kidney injuryhaptoglobinhemodialysishemolytic anemialactate dehydrogenaserelapseschistocytesthrombocytopenia

Identifiers

PMID40621293
PMCPMC12229222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.